Janet Woodcock did make clear her remarks were abo
Post# of 148185
(Total Views: 590)
Posted On: 02/04/2021 6:39:14 PM
Janet Woodcock did make clear her remarks were about those MABs targeting the virus, a caveat that I hope indicates that other MABs have a different MOA. For a while, I believe, she seemed to be aware of Leronlimab but not its MOA that did not go after the virus.
She is clear on that difference now. I believe she was commenting on the MABs she was responsible for under OWS trialing, the ACTIV ( Accelerating COVID-19 Therapeutic Interventions and Vaccines ) trials. There were five categories of these trials and ACTIV-1 was for immune modulators.
The drugs they chose to trial were not very impressive in my opinion compared to Leronlimab.
She is clear on that difference now. I believe she was commenting on the MABs she was responsible for under OWS trialing, the ACTIV ( Accelerating COVID-19 Therapeutic Interventions and Vaccines ) trials. There were five categories of these trials and ACTIV-1 was for immune modulators.
The drugs they chose to trial were not very impressive in my opinion compared to Leronlimab.
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼